The TIP study (Treat-to-target trail of basal insulin to oral therapy in post-transplant hyperglycemia) revealed that KT recipients treated with basal insulin (isophane insulin for evening blood glucose > 140 mg/dL) during the first 3 weeks after KT exhibited significantly lower HbA1C level compared to those treated with standard-of-care control (antihyperglycemic agents for blood glucose > 180–250 mg/dL) at 3 months and after 3 months over a 1 year follow-up. This evidence concerns the gene INS and Hyperglycemia.